Swinburne University of Technology
Hawthorn, Victoria, 3122, Australia
NCT Number: NCT03197974
The aim of this study is to improve outcomes in people with bipolar disorder (BD) by comparing two new online interventions specifically designed to improve quality of life amongst people who have had multiple (10 or more) episodes of BD.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Hawthorn, Victoria, 3122, Australia
People who have had significant experience with bipolar disorder (defined here as 10 or more episodes) may not benefit from existing psychosocial interventions targeting symptoms and relapse, and may be better served by interventions targeting quality of life (QoL). Our international team of researchers, clinicians and consumers has developed two different online interventions, both of which there is reason to believe will be useful. Both interventions are brief, with 4 weeks of new online content released weekly, plus one additional week of application. This 5-week 'active phase' is supported by email contact with a personal online coach. The remainder of the 6 months of participant involvement in the trial includes continued access to the website (without coaching support) and follow-up assessments. Both arms are equivalent in using cutting-edge internet technologies and design features to help people engage with the therapeutic content and generalise it into their real lives. The websites have been developed following best-practice principles of persuasive system design, and rely heavily on consumer videos, social engagement through discussion boards, personalised feedback, and intuitive content structure to maximise engagement.
Australia's NHMRC has funded a 4-year project (2016-2019) to develop and compare the effectiveness of the two websites in terms of a range of outcomes, primarily QoL. The randomized controlled trial (RCT) will definitively assess the QoL benefits of two websites for late stage Bipolar Disorder. The RCT has been designed to optimise various aims: minimise risk of bias to support definitive scientific findings (internal validity), support ready dissemination should outcomes be positive (external validity, end-user involvement), and to optimally manage the risks inherent in the population being studied. We expect to find definitive evidence of the comparative QoL benefits of the two interventions, and insights about secondary outcomes including self-rated state anxiety, self-rated depression, and clinician-rated depression. A number of clinical and functional secondary outcomes will also be explored, as will hypothesised mediators and baseline moderators of QoL outcomes. Economic analysis based on cost-consequence analysis, and a range of process evaluations will also be conducted.
A total of 300 participants will be block randomised to provide power to identify a small-moderate treatment effect on QoL. Participants will be blinded as to the experimental intervention. The study uses a single-site (internet-based) design, with advertising occurring primarily online, but also through traditional methods via clinical networks of the researchers in Australia, United Kingdom (UK), Canada and the US. Major assessment time points are baseline, post-treatment (primary endpoint), 3 months post-baseline and 6 months post-baseline. Participants will be remunerated for assessments, which include both online questionnaires and a (blinded) semi-structured clinical interview by phone.
A multi-layered risk-management approach has been developed based on our experience with online interventions for bipolar disorder and psychosis. First and foremost, we explain to participants that their participation does not replace usual care, and no emergency assistance is available through the website (a link to the international site unsuicide is provided). This devolving of responsibility to the participant is reinforced by the inclusion criterion of being under the care of a medical practitioner and having access to local emergency services. Second, both intervention sites contain general information about the potential risks (e.g., generating distress) of the interventions, as well as specific alerts to the potential challenges of particular exercises. Third, a comprehensive 'red flag decision tree' has been developed to guide the team's response to any risk issues arising (see Table 2). Finally, any adverse events arising will be reviewed weekly in the trial executive committee.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
To ensure ready translation, minimally restrictive inclusion and exclusion criteria will be set.
Inclusion criteria
Exclusion criteria
Brief online self-management program with email coaching support
Brief online self-management program with email coaching support
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
Self-report measure to assess quality of life.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A clinician-rated scale to assess depression symptoms.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A clinician-rated scale to assess manic symptoms.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of depression.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of anxiety and stress symptoms.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A clinician-rated scale to assess functioning across 6 different domains.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of sleep quality.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess overlap between sleep, circadian rhythms and mood.
Time frame: Immediately post-intervention (post the 5 week active phase), 3 and 6 months.
Using the Time to Intervention for Mood Episode (TIME) and a modified version of the MINI International Neuropsychiatric Interview (MINI) to determine treatment-related relapse events.
Time frame: Baseline, 3 and 6 months.
A self-report measure of health service use.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of quality of life.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of mindfulness.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of self-compassion.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess multiple aspects of emotion dysregulation.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure of tendency to ruminate.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess rumination and dampening.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess non-attachment to self.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess self-criticism.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
A self-report measure to assess perfectionism.
Time frame: Baseline, immediately post-intervention (post the 5 week active phase), 3 and 6 months.
Self-reported adherence to medication.
Swinburne University of Technology
Other
Web-based Intervention With Email Support to Improve Quality of Life in Late Stage Bipolar Disorder (ORBIT): Randomised Controlled Trial
Acronym: ORBIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07404943
Behavior, Bi-Polar Disorder
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT06365021
Bipolar Disorder, Bipolar and Related Disorders
São Paulo, Brazil
View Trial DetailsNCT06462586
Bipolar Disorder, Bipolar Disorder, Manic
Rogers, Arkansas, United States
View Trial DetailsNCT06462612
Bipolar Disorder, Bipolar Disorder, Manic
Bentonville, Arkansas, United States
View Trial Details